$155M Series B investment into preclin #ADAR Therapeutics Co #Airna, highlighting strong interest in modality despite challenging biotech environment.
$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro
$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro
AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline — Airna
Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new
airna.com
April 8, 2025 at 5:03 PM
$155M Series B investment into preclin #ADAR Therapeutics Co #Airna, highlighting strong interest in modality despite challenging biotech environment.
$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro
$ to be used to advance AATD candidate into clinc + develop cardiometabolic candidates: airna.com/news/airna-r... #ProQR #WaveLifeSciences #Korro
ProQR Therapeutics: Innovativer Vorreiter im Bereich RNA-Editing erhält Übergewichts-Rating von Cantor Fitzgerald
https://dasgeld.co/posts/FB86E5AD-F99E-4ACA-93C2-521A9911E5D2
https://dasgeld.co/posts/FB86E5AD-F99E-4ACA-93C2-521A9911E5D2
May 26, 2025 at 2:41 PM
ProQR Therapeutics: Innovativer Vorreiter im Bereich RNA-Editing erhält Übergewichts-Rating von Cantor Fitzgerald
https://dasgeld.co/posts/FB86E5AD-F99E-4ACA-93C2-521A9911E5D2
https://dasgeld.co/posts/FB86E5AD-F99E-4ACA-93C2-521A9911E5D2
Fuchs Endothelial Corneal Dystrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen
Fuchs Endothelial Corneal Dystrophy Market To Reach New Heights In Growth By 2034, DelveInsight Predicts | ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen | PressReleaseCC
www.pressreleasecc.com
July 7, 2025 at 5:13 PM
Fuchs Endothelial Corneal Dystrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ProQR Therapeutics, Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon Inc., Emmecell, Santen
ProQR Therapeutics #PRQR - large shareholder is angry that the board of directors is ignoring shareholder concerns - Van Herk is the shareholder and details are in the 13D. If you are a shareholder in a micro cap often the only way for you to get treated fairly is to run a proxy contest.
May 29, 2025 at 6:45 PM
ProQR Therapeutics #PRQR - large shareholder is angry that the board of directors is ignoring shareholder concerns - Van Herk is the shareholder and details are in the 13D. If you are a shareholder in a micro cap often the only way for you to get treated fairly is to run a proxy contest.
October marks #RettSyndromeAwarenessMonth, a time to shine a light on Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
October 22, 2025 at 1:05 PM
October marks #RettSyndromeAwarenessMonth, a time to shine a light on Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.
ProQR Receives Orphan Drug Status for F508del Therapy http://wp.me/p40DH9-8
December 3, 2024 at 2:03 AM
ProQR Receives Orphan Drug Status for F508del Therapy http://wp.me/p40DH9-8
As an apparently long-time shareholder, he is disappointed with mgmt/Board performance, including not expanding Lilly deal and finding additional partnerships. #ProQR
May 29, 2025 at 12:47 PM
As an apparently long-time shareholder, he is disappointed with mgmt/Board performance, including not expanding Lilly deal and finding additional partnerships. #ProQR
Lemelinda pairs her passion for RNA biology with research, protocol development & biosafety support, while also fostering a strong community at ProQR through our Coffee & Collaboration Café.
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
August 26, 2025 at 9:36 AM
Lemelinda pairs her passion for RNA biology with research, protocol development & biosafety support, while also fostering a strong community at ProQR through our Coffee & Collaboration Café.
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
Meet more of the ProQR team at: bit.ly/45ZFtmq
#Axiomer #RNAEditing #TeamProQR
David, Senior Scientist at ProQR, plays a key role in advancing cell biology research while also contributing to team leadership and workplace culture.
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
October 15, 2025 at 9:47 AM
David, Senior Scientist at ProQR, plays a key role in advancing cell biology research while also contributing to team leadership and workplace culture.
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
Meet the rest of our team at: bit.ly/4nbVZWR
#Axiomer #RNAEditing #TeamProQR
ProQR retains key patent for RNA editing technology -… https://news.google.com/rss/articles/CBMia2h0dHBzOi8vbmcuaW52ZXN0aW5nLmNvbS9uZXdzL2NvbXBhbnktbmV3cy9wcm9xci1yZXRhaW5zLWtleS1wYXRlbnQtZm9yLXJuYS1lZGl0aW5nLXRlY2hub2xvZ3ktOTNDSC0xMzA5NzQ50gEA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
April 20, 2024 at 1:49 AM
Marshall Wace LLP Invests $158,000 in ProQR Therapeutics (NASDAQ:PRQR) Marshall Wace LLP acquired...
https://www.etfdailynews.com/2025/05/06/marshall-wace-llp-invests-158000-in-proqr-therapeutics-nasdaqprqr/
#Markets #SEC #Filing #Articles
Result Details
https://www.etfdailynews.com/2025/05/06/marshall-wace-llp-invests-158000-in-proqr-therapeutics-nasdaqprqr/
#Markets #SEC #Filing #Articles
Result Details
Marshall Wace LLP Invests $158,000 in ProQR Therapeutics (NASDAQ:PRQR)
Marshall Wace LLP acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 59,515 shares of the biopharmaceutical company’s stock, valued at approximately $158,000. Marshall Wace LLP owned 0.07% of ProQR Therapeutics […]
www.etfdailynews.com
May 6, 2025 at 10:07 AM
Marshall Wace LLP Invests $158,000 in ProQR Therapeutics (NASDAQ:PRQR) Marshall Wace LLP acquired...
https://www.etfdailynews.com/2025/05/06/marshall-wace-llp-invests-158000-in-proqr-therapeutics-nasdaqprqr/
#Markets #SEC #Filing #Articles
Result Details
https://www.etfdailynews.com/2025/05/06/marshall-wace-llp-invests-158000-in-proqr-therapeutics-nasdaqprqr/
#Markets #SEC #Filing #Articles
Result Details
ProQR Therapeutics: Ein vielversprechender Biotechnologie-Akteur mit neuem Outperform-Rating von Evercore ISI
https://dasgeld.co/posts/232012FE-A0D5-4369-BEE9-5A0AE3EECBB6
https://dasgeld.co/posts/232012FE-A0D5-4369-BEE9-5A0AE3EECBB6
May 26, 2025 at 12:18 PM
ProQR Therapeutics: Ein vielversprechender Biotechnologie-Akteur mit neuem Outperform-Rating von Evercore ISI
https://dasgeld.co/posts/232012FE-A0D5-4369-BEE9-5A0AE3EECBB6
https://dasgeld.co/posts/232012FE-A0D5-4369-BEE9-5A0AE3EECBB6
No, unfortunately. We should see the voting results soon. No filings yet. The message should be clear: more urgency, plus I want to see the NTCP preclinical package when #ProQR announce CTA.
June 3, 2025 at 4:13 PM
No, unfortunately. We should see the voting results soon. No filings yet. The message should be clear: more urgency, plus I want to see the NTCP preclinical package when #ProQR announce CTA.
#PRQR ProQR Announces Second Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
ProQR Announces Second Quarter 2025 Operating and Financial Results
ProQR Therapeutics (Nasdaq: PRQR) reported its Q2 2025 financial and operational results, highlighting significant progress in its RNA editing pipeline. The company has submitted a Clinical Trial Application for AX-0810, its lead program targeting NTCP for cholestatic diseases, with initial Phase 1 data expected in Q4 2025.ProQR maintains a strong financial position with €119.8 million in cash, providing runway into mid-2027. The company reported a net loss of €22.3 million for H1 2025. Notable developments include advancing AX-2402 for Rett Syndrome and achieving $2.0 million in milestone payments from its Eli Lilly collaboration, with potential for additional milestone income and expansion options.
www.stocktitan.net
August 7, 2025 at 11:00 AM
#PRQR ProQR Announces Second Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-second-quarter-2025-operating-and-financial-3dney9j6qc9i.html
#PRQR ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
#news #investing #stocks
https://www.stocktitan.net/news/PRQR/pro-qr-therapeutics-announces-8-1-million-in-new-funding-from-rett-y7k961jw6tpv.html
#news #investing #stocks
https://www.stocktitan.net/news/PRQR/pro-qr-therapeutics-announces-8-1-million-in-new-funding-from-rett-y7k961jw6tpv.html
ProQR Secures $8.1M Funding Boost to Advance Revolutionary Rett Syndrome Treatment
ProQR expands collaboration with RSRT, securing $9.1M total funding to develop RNA-editing therapy for Rett syndrome, targeting 350,000 patients worldwide.
www.stocktitan.net
December 11, 2024 at 12:00 PM
#PRQR ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
#news #investing #stocks
https://www.stocktitan.net/news/PRQR/pro-qr-therapeutics-announces-8-1-million-in-new-funding-from-rett-y7k961jw6tpv.html
#news #investing #stocks
https://www.stocktitan.net/news/PRQR/pro-qr-therapeutics-announces-8-1-million-in-new-funding-from-rett-y7k961jw6tpv.html
JUST IN: ( NASDAQ: #PRQR ) ProQR Announces Second Quarter 2024 Operating and Financial Results
#StockMarket #News
#StockMarket #News
August 8, 2024 at 6:50 PM
JUST IN: ( NASDAQ: #PRQR ) ProQR Announces Second Quarter 2024 Operating and Financial Results
#StockMarket #News
#StockMarket #News
As R&D Team Manager at ProQR, Lorenza drives scientific collaboration and project planning while also championing inclusivity as part of our DEI team.
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
July 22, 2025 at 8:45 AM
As R&D Team Manager at ProQR, Lorenza drives scientific collaboration and project planning while also championing inclusivity as part of our DEI team.
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
Meet the ProQR team at: bit.ly/4m4oZzs
#Axiomer #RNAEditing #TeamProQR
ProQR Receives Orphan Drug Status for F508del Therapy http://wp.me/p3pm8R-5Q
December 3, 2024 at 2:13 AM
ProQR Receives Orphan Drug Status for F508del Therapy http://wp.me/p3pm8R-5Q
ProQR is officially a Great Place to Work!
We’re proud to foster a culture where innovation, collaboration, and growth thrive—driven by our amazing team and our mission to develop transformative RNA therapies.
bit.ly/42LdvZR
#GPTW #Biotech #RNAEditing #Axiomer
We’re proud to foster a culture where innovation, collaboration, and growth thrive—driven by our amazing team and our mission to develop transformative RNA therapies.
bit.ly/42LdvZR
#GPTW #Biotech #RNAEditing #Axiomer
April 25, 2025 at 8:00 AM
ProQR is officially a Great Place to Work!
We’re proud to foster a culture where innovation, collaboration, and growth thrive—driven by our amazing team and our mission to develop transformative RNA therapies.
bit.ly/42LdvZR
#GPTW #Biotech #RNAEditing #Axiomer
We’re proud to foster a culture where innovation, collaboration, and growth thrive—driven by our amazing team and our mission to develop transformative RNA therapies.
bit.ly/42LdvZR
#GPTW #Biotech #RNAEditing #Axiomer
ProQR defends RNA editing platform at EPO |… https://news.google.com/rss/articles/CBMidWh0dHBzOi8vd3d3LmxpZmVzY2llbmNlc2lwcmV2aWV3LmNvbS9iaW90ZWNobm9sb2d5L3Byb3FyLWNvbnRpbnVlcy10by1kZWZlbmQtYXhpb21lci1wYXRlbnRzLWFzLWVwby1yZWplY3RzLWNoYWxsZW5nZdIBAA?oc=5&utm_source=dlvr.it&utm_medium=bluesky
April 23, 2024 at 9:03 PM
ProQR $PRQR to host a 2.5 hour discussion on two targets nearing the clinic this coming wednesday:
www.proqr.com/events/2024-...
www.proqr.com/events/2024-...
Analyst and Investor Event
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Manageme...
www.proqr.com
December 7, 2024 at 11:49 PM
ProQR $PRQR to host a 2.5 hour discussion on two targets nearing the clinic this coming wednesday:
www.proqr.com/events/2024-...
www.proqr.com/events/2024-...
#ADARediting $PRQR quarterly update. All you need to know:
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
ProQR Announces First Quarter 2025 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened ...
finance.yahoo.com
May 8, 2025 at 1:42 PM
#ADARediting $PRQR quarterly update. All you need to know:
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
#PRQR ProQR Announces Third Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
www.stocktitan.net
November 6, 2025 at 12:00 PM
#PRQR ProQR Announces Third Quarter 2025 Operating and Financial Results
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html
https://www.stocktitan.net/news/PRQR/pro-qr-announces-third-quarter-2025-operating-and-financial-6wi5wxiaj38b.html